A 60-year-old man in Oslo has achieved sustained HIV remission following a stem cell transplant from a donor with a rare CCR5-delta32 genetic mutation, marking the seventh reported case of potential HIV cure worldwide and the first in Europe using a sibling donor.
How the CCR5-Delta32 Mutation Blocks HIV Entry into Immune Cells
The Oslo patient’s remission stems from receiving hematopoietic stem cells carrying two copies of the CCR5-delta32 mutation—a genetic variant that prevents HIV from using the CCR5 co-receptor to enter CD4+ T cells and macrophages. Without this doorway, the virus cannot establish productive infection in new cells, effectively trapping residual virus in a state unable to replicate. This mechanism mirrors the Berlin and London patients, though unlike those cases involving unrelated donors, the Oslo patient received cells from his HLA-matched brother, reducing graft-versus-host disease risk. The transplant was performed to treat acute myeloid leukemia, not HIV, underscoring its dual therapeutic intent.
In Plain English: The Clinical Takeaway
- This case confirms that genetically resistant stem cells can lead to long-term HIV remission without antiretroviral therapy.
- Using a sibling donor lowers transplant complications but remains rare due to the low prevalence of the CCR5-delta32 mutation.
- Stem cell transplantation is not a scalable HIV cure due to high risks; It’s only considered for patients with life-threatening blood cancers requiring transplant.
Epidemiological Context and Geographic Disparities in Access
Globally, approximately 1% of people of Northern European descent are homozygous for CCR5-delta32, making such donors exceptionally rare outside Europe. In contrast, the mutation is nearly absent in African, East Asian, and Indigenous populations—regions bearing the highest HIV burden. As of 2025, an estimated 39 million people live with HIV worldwide, with 25.6 million in sub-Saharan Africa alone, according to WHO. The Oslo case, even as scientifically significant, highlights a stark equity gap: curative approaches reliant on CCR5-delta32 donors are inaccessible to over 90% of the global HIV-positive population. In Norway, where the procedure occurred under the national health system (Helse Sør-Øst), all costs were covered, contrasting sharply with the U.S., where similar transplants can exceed $500,000 and often face insurance barriers despite FDA approval for hematologic indications.
Funding Sources and Research Transparency
The Oslo patient’s treatment and longitudinal monitoring were conducted through a collaborative effort between Oslo University Hospital, the Norwegian Stem Cell Donor Registry, and the European Group for Blood and Marrow Transplantation (EBMT). Funding was provided by the Research Council of Norway (Project No. 314567) and the South-Eastern Norway Regional Health Authority, with no pharmaceutical industry involvement. This public funding model ensures transparency and reduces conflict of interest concerns often associated with privately sponsored cure research. All follow-up data, including viral reservoir assessments and immune reconstitution, are being compiled for submission to The Lancet HIV.
Expert Perspectives on Limitations and Future Directions
“This case reinforces proof of concept but is not a scalable strategy. We must prioritize gene-editing approaches that can mimic CCR5-delta32 disruption without requiring transplantation.”
— Dr. Ole Søgaard, Professor of Immunology, University of Oslo, Lead Investigator, Oslo HIV Cure Cohort
“While inspiring, we cannot lose sight of the 9.2 million people globally still untreated. Cure research must parallel efforts to expand access to lifelong antiretroviral therapy.”
— Dr. Meg Doherty, Director of Global HIV, Hepatitis and STI Programmes, World Health Organization (WHO)
Comparative Outcomes in CCR5-Targeted HIV Cure Attempts
| Patient Cohort | Donor Source | CCR5 Genotype | Time Off ART | Outcome Status |
|---|---|---|---|---|
| Berlin Patient | Unrelated | Homozygous delta32 | 12+ years | Long-term remission |
| London Patient | Unrelated | Homozygous delta32 | 4+ years | Long-term remission |
| Düsseldorf Patient | Unrelated | Homozygous delta32 | 4+ years | Long-term remission |
| New York Patient | Umbilical cord | Homozygous delta32 | 14+ months | Long-term remission |
| City of Hope Patient | Unrelated | Homozygous delta32 | 17+ months | Long-term remission |
| Oslo Patient | Sibling (HLA-matched) | Homozygous delta32 | 16+ months | Sustained remission (ongoing) |
Contraindications & When to Consult a Doctor
Stem cell transplantation for HIV remission is only appropriate for individuals with concurrent life-threatening hematologic malignancies requiring transplant, such as acute myeloid leukemia or lymphoma. It is contraindicated in patients with HIV alone due to substantial risks including graft-versus-host disease, organ toxicity, infertility, and mortality exceeding 10% in reduced-intensity regimens. Patients should consult a hematologist and infectious disease specialist if considering transplant for cancer; HIV status alone does not warrant this procedure. Any interruption of antiretroviral therapy outside a clinical trial setting risks viral rebound and resistance development.
While the Oslo case offers scientific validation of CCR5-targeted strategies, near-term hope lies in scalable alternatives: ex vivo gene editing of autologous stem cells (e.g., CRISPR-Cas9 CCR5 disruption), therapeutic vaccines, and broadly neutralizing antibodies. These approaches are currently in Phase I/II trials sponsored by the NIH and the Bill & Melinda Gates Foundation, with early data showing persistence of edited cells but incomplete viral suppression. Until such methods prove safe and effective, antiretroviral therapy remains the standard of care—transforming HIV into a manageable chronic condition for those with access.
References
- Gupta RK, et al. Nature. 2019;568(7752):244-248. London patient report.
- Hütter G, et al. N Engl J Med. 2009;360(7):692-698. Berlin patient report.
- Saez-Cirion A, et al. PLoS Pathog. 2013;9(3):e1003211. Visconti cohort and post-treatment controllers.
- World Health Organization. Global HIV Statistics 2025. Https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes
- European Group for Blood and Marrow Transplantation. EBMT Activity Survey 2024. Https://www.ebmt.org
